Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

odanacatib

Novartis day

Novartis gets EU approval for Bexsero meningitis B shot

Offers protection for all ages above two months

- PMLiVE

Novartis’ eye drug Jetrea recommended for EU approval

Set to become first drug treatment for sight-threatening condition vitreomacular traction and macular hole

- PMLiVE

EMA recommends suspension of Merck’s Tredaptive

Pharma company had already anticipated decision by withdrawing product worldwide

- PMLiVE

Amgen’s Aranesp disappoints in heart failure

Red blood cell stimulator no better than placebo

- PMLiVE

Amgen invests $200m in Singapore monoclonal antibody facility

New manufacturing plant will produce both clinical and commercial products

- PMLiVE

Merck suspends Tredaptive worldwide

Trial demonstrates increased risk of serious adverse events

- PMLiVE

NHS failing to promote clinical trials to patients

NIHR mystery shoppers report says 91 per cent of sites have no information in reception area

UCB launches arthritis exercise programme in the UK

Scheme was piloted at two NHS Trusts during 2011

Novartis building

Novartis parts with Eisai to go it alone with COPD drugs

Ends co-promotion agreement for Onbrez, Seebri and QVA149

- PMLiVE

Amgen signs $180m nanotechnology cancer deal

Will combine BIND Biosciences' tissue-targeting technology with a molecularly-targeted drug

- PMLiVE

NICE set to approve Novartis eye drug Lucentis

Final draft guidance says treatment is cost-effective in diabetic macular oedema

- PMLiVE

India’s Supreme Court wants tighter clinical trial regulation

Justice Lodha says illegal studies of investigational medicines causing “havoc to human life”

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links